Literature DB >> 17202219

Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.

Sandra M Mueller1, Birgit Schaetz, Kathrin Eismann, Silke Bergmann, Michael Bauerle, Matthias Schmitt-Haendle, Hauke Walter, Barbara Schmidt, Klaus Korn, Heinrich Sticht, Bernd Spriewald, Ellen G Harrer, Thomas Harrer.   

Abstract

To determine the influence of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells on the development of drug resistance mutations in the HIV-1 protease, we analyzed protease sequences from viruses from a human leukocyte antigen class I (HLA class I)-typed cohort of 94 HIV-1-positive individuals. In univariate statistical analyses (Fisher's exact test), minor and major drug resistance mutations as well as drug-associated polymorphisms showed associations with HLA class I alleles. All correlations with P values of 0.05 or less were considered to be relevant without corrections for multiple tests. A subset of these observed correlations was experimentally validated by enzyme-linked immunospot assays, allowing the definition of 10 new epitopes recognized by CD8+ T cells from patients with the appropriate HLA class I type. Several drug resistance-associated mutations in the protease acted as escape mutations; however, cells from many patients were still able to generate CD8+ T cells targeting the escape mutants. This result presumably indicates the usage of different T-cell receptors by CD8+ T cells targeting these epitopes in these patients. Our results support a fundamental role for HLA class I-restricted immune responses in shaping the sequence of the HIV-1 protease in vivo. This role may have important clinical implications both for the understanding of drug resistance pathways and for the design of therapeutic vaccines targeting drug-resistant HIV-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202219      PMCID: PMC1866003          DOI: 10.1128/JVI.01547-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype.

Authors:  John Sidney; Scott Southwood; Valerie Pasquetto; Alessandro Sette
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

Review 2.  The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy.

Authors:  Jianming Tang; Richard A Kaslow
Journal:  AIDS       Date:  2003       Impact factor: 4.177

3.  Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses.

Authors:  Florian Bihl; Nicole Frahm; Loriana Di Giammarino; John Sidney; Mina John; Karina Yusim; Tonia Woodberry; Kaori Sango; Hannah S Hewitt; Leah Henry; Caitlyn H Linde; John V Chisholm; Tauheed M Zaman; Eunice Pae; Simon Mallal; Bruce D Walker; Alessandro Sette; Bette T Korber; David Heckerman; Christian Brander
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

4.  Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein.

Authors:  M Del Val; H J Schlicht; T Ruppert; M J Reddehase; U H Koszinowski
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

5.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

6.  The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Authors:  N Saitou; M Nei
Journal:  Mol Biol Evol       Date:  1987-07       Impact factor: 16.240

7.  Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity.

Authors:  A Propato; E Schiaffella; E Vicenzi; V Francavilla; L Baloni; M Paroli; L Finocchi; N Tanigaki; S Ghezzi; R Ferrara; R Chesnut; B Livingston; A Sette; R Paganelli; F Aiuti; G Poli; V Barnaba
Journal:  Hum Immunol       Date:  2001-06       Impact factor: 2.850

8.  Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.

Authors:  H Walter; B Schmidt; K Korn; A M Vandamme; T Harrer; K Uberla
Journal:  J Clin Virol       Date:  1999-06       Impact factor: 3.168

Review 9.  The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.

Authors:  Dan Turner; Jonathan M Schapiro; Bluma G Brenner; Mark A Wainberg
Journal:  Antivir Ther       Date:  2004-06

10.  Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.

Authors:  Alasdair Leslie; Daniel Kavanagh; Isobella Honeyborne; Katja Pfafferott; Charles Edwards; Tilly Pillay; Louise Hilton; Christina Thobakgale; Danni Ramduth; Rika Draenert; Sylvie Le Gall; Graz Luzzi; Anne Edwards; Christian Brander; Andrew K Sewell; Sarah Moore; James Mullins; Corey Moore; Simon Mallal; Nina Bhardwaj; Karina Yusim; Rodney Phillips; Paul Klenerman; Bette Korber; Photini Kiepiela; Bruce Walker; Philip Goulder
Journal:  J Exp Med       Date:  2005-03-21       Impact factor: 14.307

View more
  14 in total

1.  Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol.

Authors:  A C Karlsson; J M Chapman; B D Heiken; R Hoh; E G Kallas; J N Martin; F M Hecht; S G Deeks; D F Nixon
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Control of M184V HIV-1 mutants by CD8 T-cell responses.

Authors:  Thomas Vollbrecht; Josef Eberle; Julia Roider; Silja Bühler; Renate Stirner; Nadja Henrich; Ulrich Seybold; Johannes R Bogner; Rika Draenert
Journal:  Med Microbiol Immunol       Date:  2011-12-27       Impact factor: 3.402

3.  CD4+ T cells from HIV-1-infected patients recognize wild-type and mutant human immunodeficiency virus-1 protease epitopes.

Authors:  N G Muller; R Alencar; L Jamal; J Hammer; J Sidney; A Sette; R M Brindeiro; J Kalil; E Cunha-Neto; S L Moraes
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

4.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

5.  Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study.

Authors:  Santiago Avila-Rios; Christopher E Ormsby; Jonathan M Carlson; Humberto Valenzuela-Ponce; Juan Blanco-Heredia; Daniela Garrido-Rodriguez; Claudia Garcia-Morales; David Heckerman; Zabrina L Brumme; Simon Mallal; Mina John; Enrique Espinosa; Gustavo Reyes-Teran
Journal:  Retrovirology       Date:  2009-08-10       Impact factor: 4.602

6.  Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.

Authors:  Art F Y Poon; Sergei L Kosakovsky Pond; Douglas D Richman; Simon D W Frost
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

7.  Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.

Authors:  Francesca Razzolini; Francesco Saladini; Lisa Malincarne; Ilaria Vicenti; Nicola Palladino; Laura Romano; Daniela Francisci; Maurizio Zazzi
Journal:  J Clin Microbiol       Date:  2008-09-24       Impact factor: 5.948

8.  Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.

Authors:  Monika Tschochner; Abha Chopra; Tanya M Maiden; Imran F Ahmad; Ian James; Hansjakob Furrer; Huldrych F Günthard; Simon Mallal; Andri Rauch; Mina John
Journal:  Antivir Ther       Date:  2009

9.  Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

Authors:  Stephane Champiat; Rui André Saraiva Raposo; Nicholas J Maness; John L Lehman; Sean E Purtell; Aaron M Hasenkrug; Jacob C Miller; Hansi Dean; Wayne C Koff; Marisa Ailin Hong; Jeffrey N Martin; Steven G Deeks; Gerald E Spotts; Christopher D Pilcher; Fredrick M Hecht; Esper G Kallas; Keith E Garrison; Douglas F Nixon
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it?

Authors:  Dorian McIlroy
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.